Health Canada consultation on reducing youth access and appeal of vaping products
https://policybase.cma.ca/link/policy14078

POLICY TYPE  Response to consultation
DATE  2019-05-24
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
Population health, health equity, public health

Documents
Cannabis for Medical Purposes

https://policybase.cma.ca/link/policy10045

POLICY TYPE
Policy document

LAST REVIEWED
2019-03-03

DATE
2010-12-04

TOPICS
Pharmaceuticals, prescribing, cannabis, drugs

Documents

CANNABIS FOR MEDICAL PURPOSES

CMA POLICY

Cannabis for Medical Purposes

The Canadian Medical Association (CMA) recognizes the unique requirements of those individuals suffering from terminal illnesses or chronic diseases for which conventional pharmaceutical therapies are ineffective or contraindicated.

There have been numerous requests for the increase in use of cannabis by medical practitioners and others who promote its use for medical purposes. The CMA has long supported the compassionate access to cannabis for the relief of suffering.

The CMA reviews the following recommendations:

1. Increase support for the advancement of scientific knowledge about the medical use of cannabis. The CMA recommends the establishment of ongoing research into clinical data, including efficacy, toxicity, and interactions with other medications. Such research is critical to ensure the safe and effective use of cannabis in a medical setting.

2. Support the development of regulations and protocols to ensure the safe and effective use of cannabis in medical settings. The CMA recommends collaboration with health authorities and other stakeholders to develop guidelines for safe and effective use.

3. Increase support for advocacy on the legal status of cannabis for medical purposes. The CMA recommends collaboration with other stakeholders to advocate for legal reforms that would facilitate the medical use of cannabis.

4. Support the development of educational resources for healthcare providers. The CMA recommends the development of educational materials to help healthcare providers understand the medical use of cannabis and to guide them in providing appropriate care.

5. Increase support for research into the therapeutic potential of cannabis. The CMA recommends collaboration with researchers and other stakeholders to fund research into the therapeutic potential of cannabis and to share the results of these studies.

The CMA believes that the medical use of cannabis has significant potential for the relief of suffering and the enhancement of the quality of life for those individuals who require its use.
Medication use and seniors (Update 2017)
https://policybase.cma.ca/link/policy10151

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2011-05-28
REPLACES  Medication use and seniors
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs

Documents
Vision for e-Prescribing: a joint statement by the Canadian Medical Association and the Canadian Pharmacists Association

https://policybase.cma.ca/link/policy10670

POLICY TYPE  Policy document
LAST REVIEWED  2019-03-03
DATE  2012-12-08
TOPICS  Health information and e-health
Pharmaceuticals, prescribing, cannabis, drugs

Documents
Health Canada consultation on edible cannabis, extracts & topicals
https://policybase.cma.ca/link/policy14020

POLICY TYPE  Response to consultation
DATE  2019-02-20
TOPICS  Pharmaceuticals, prescribing, cannabis, drugs
  Population health, health equity, public health

Documents